Technical Analysis for AKTX - Akari Therapeutics Plc

Grade Last Price % Change Price Change
grade B 2.19 1.86% 0.04
AKTX closed up 1.86 percent on Wednesday, June 3, 2020, on 59 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical AKTX trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Upper Bollinger Band Walk Strength 1.86%
Wide Bands Range Expansion 1.86%
Upper Bollinger Band Touch Strength 1.86%
Above Upper BB Strength -0.45%
Upper Bollinger Band Touch Strength -0.45%
Calm After Storm Range Contraction 7.35%
Calm After Storm Range Contraction 9.50%
Narrow Range Bar Range Contraction 9.50%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company develops Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b – 9 (membrane attack complex or MAC). It develops products to treat rare diseases, such as paroxysmal nocturnal haemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis (MG), Guillain Barré syndrome (GBS), and Sjögren's syndrome. The company was formerly known as Volution Immuno Pharmaceuticals SA and changed its name to Akari Therapeutics, Plc in September 2015. The company is based in New York, New York. Akari Therapeutics, Plc operates as a subsidiary of RPC Pharma Limited.
Medicine Biopharmaceutical Medical Specialties Organ Systems Rare Diseases Autoimmunity Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Myasthenia Gravis Alexion Pharmaceuticals Atypical Hemolytic Uremic Syndrome Complement System Sjögren's Syndrome

Is AKTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.35
52 Week Low 0.87
Average Volume 191,338
200-Day Moving Average 1.80
50-Day Moving Average 1.73
20-Day Moving Average 1.95
10-Day Moving Average 2.07
Average True Range 0.17
ADX 37.27
+DI 35.40
-DI 9.19
Chandelier Exit (Long, 3 ATRs ) 2.06
Chandelier Exit (Short, 3 ATRs ) 2.12
Upper Bollinger Band 2.24
Lower Bollinger Band 1.65
Percent B (%b) 0.91
BandWidth 30.42
MACD Line 0.12
MACD Signal Line 0.10
MACD Histogram 0.0163
Fundamentals Value
Market Cap 25.79 Million
Num Shares 11.8 Million
EPS -2.00
Price-to-Earnings (P/E) Ratio -1.10
Price-to-Sales 0.00
Price-to-Book 2.11
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.33
Resistance 3 (R3) 2.32 2.26 2.30
Resistance 2 (R2) 2.26 2.23 2.27 2.29
Resistance 1 (R1) 2.23 2.21 2.20 2.24 2.29
Pivot Point 2.17 2.17 2.16 2.18 2.17
Support 1 (S1) 2.14 2.14 2.11 2.15 2.09
Support 2 (S2) 2.08 2.12 2.09 2.09
Support 3 (S3) 2.05 2.08 2.08
Support 4 (S4) 2.06